On May 17, 2022 Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that Management will participate in the upcoming investor events set out below (Press release, Transgene, MAY 17, 2022, View Source [SID1234614757]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– UBS Global Healthcare Conference
May 23-25, 2022
New York City, NY, USA

– Spring European MidCap Event
June 23-24, 2022
Paris, France

– Conference Portzamparc
June 29, 2022
Paris, France

On May 17, 2022 Medivir AB (Nasdaq Stockholm: MVIR) reported that the company will present at the ABGSC Life Science Summit on May 18, 2022. The company will be represented by CEO Jens Lindberg (Press release, Medivir, MAY 17, 2022, View Source [SID1234614773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

On May 17, 2022 EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, reported four senior leaders have been named to the prestigious PM360 ELITE List for 2022 (Press release, EVERSANA, MAY 17, 2022, View Source [SID1234614724]). Now in its eighth year, the PM360 ELITE (Exceptional, Leaders, Innovators, Transformers, Entrepreneurs) represents the most influential people in the healthcare industry today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Lang, CEO, and Faruk Capan, Chief Innovation Officer and CEO of Intouch Group, an EVERSANA Company, were recognized together in the Transformational Leader category. Lang and Capan have closely worked together over the past six months as Intouch Group continues its integration with EVERSANA. Their combined vision to join forces to create a next-generation marketing agency for the pharmaceutical industry was announced in late 2021. This is the second consecutive year Lang has been named in this category.

Amy Peek, Executive Director, Talent Acquisition, Field Deployment Solutions, has been named in the Talent Acquisition Leader category. Amy leads the recruitment arm for EVERSANA’s field deployment team, which recruits and hires hundreds of pharmaceutical sales representatives, medical science liaisons and other deployment professionals each year for clients.

Nicholas Capanear, Senior Vice President and Executive Craft Director at Intouch Group, an EVERSANA Company, has been named in PM360’s Creative Director category. Capanear has helped the Intouch creative team reach new heights since joining the team in early 2021.

"It’s an honor to see colleagues across EVERSANA be recognized by their peers and industry publications like PM360 as industry leaders," said Jim Lang, CEO, EVERSANA. "Being named to this list speaks to each winner’s accomplishments while reinforcing the type of top talent we aspire to find and retain across our organization. Congrats to everyone on this year’s ELITE 100 list for your many contributions to the pharma industry."

The annual award recognizes individuals and teams who have made a significant impact on the life sciences and healthcare industries throughout their careers. Winners are profiled in PM360’s May 2022 issue, which can be found here.

On May 17, 2022 NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the Jefferies Healthcare Conference in June 2022 (Press release, Nanobiotix, MAY 17, 2022, View Source [SID1234614741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

Jefferies Healthcare Conference

Presentation Date: Wednesday, June 8th, 2022
Time: 1:00 PM ET
A live webcast of the presentation will be available on the events page of the Investors section of the Company’s website. A replay will be available on the Nanobiotix website within 48 hours of the event. The Company’s corporate presentation can be downloaded here.

On May 17, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx (Press release, Ambrx, MAY 17, 2022, View Source [SID1234614758]). Dr. Lu is a distinguished clinical professor of medicine who has more than 18 years of experience in leading clinical trials and breast cancer drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to welcome Janice Lu to the Ambrx team and look forward to leveraging her insight in breast oncology to continue to progress ARX788 through the clinic," said Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx. "Janice has been a valuable asset as a principal investigator for multiple Ambrx trials, including the Phase 1 ACE-Pan Tumor-01 and Phase 2 ACE-Breast-03 clinical trials, and is the ideal candidate to take the role of CMO at our company. I look forward to leaning on Janice’s expertise to further our current research and development efforts in the treatment of oncology."

"I am impressed with the encouraging data from the ongoing clinical trials of ARX788 and Ambrx’s engineered precision biologics technology platform," said Dr. Lu. "I am excited to begin working with Ambrx in this new capacity, assisting with the ongoing development of their clinical development pipeline and overseeing the clinical operations. I believe our consorted efforts will potentially provide therapeutic treatment options that are less toxic and highly targeted to patients suffering from breast, gastric, and other solid tumors."

Dr. Lu has spent her career focused on managing the treatment of women with breast cancer. Prior to her role at Ambrx, Dr. Lu was a Clinical Professor of Medicine and Medical Director of the Breast Oncology Program at the Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center. Prior to her role at USC, Dr. Lu was an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at the University of California, Los Angeles. Dr. Lu, a board certified medical oncologist, began her career at SUNY Stony Brook where she served as the Director of Breast Medical Oncology for several years.

Dr. Lu received a M.D. from Peking University School of Medicine as well as a Ph.D. from Syracuse University focusing on epigenetics under the mentorship of Dr. David Allis (Rockefeller University). Dr. Lu completed her Hematology and Oncology Fellowship at New York University School of Medicine.